Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma

Background: The anti-angiogenic Sorafenib is the only approved systemic therapy for advanced hepatocellular carcinoma (HCC). However, acquired resistance limits its efficacy. An emerging theory to explain intrinsic resistance to other anti-angiogenic drugs is ‘vessel co-option,’ ie, the ability of t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Natl Cancer Inst
Main Authors: Kuczynski, Elizabeth A., Yin, Melissa, Bar-Zion, Avinoam, Lee, Christina R., Butz, Henriett, Man, Shan, Daley, Frances, Vermeulen, Peter B., Yousef, George M., Foster, F. Stuart, Reynolds, Andrew R., Kerbel, Robert S.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2016
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5017954/
https://ncbi.nlm.nih.gov/pubmed/27059374
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djw030
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados